Hosted on MSN11mon
Genmab joins ADC arena with $1.8bn ProfoundBio acquisitionThe drug gained full approval in January this year. Also in ProfoundBio’s pipeline are ADC candidates that target CD70, PTK7 and EGFR in solid tumour and haematological malignancy indications.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback